Personalized chemotherapy for lung cancer based on DNA test
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet.
- Your cancer is considered removable by a team of doctors.
- If you have non-squamous cancer, it must not have certain gene mutations (EGFR/ALK).
- You are well enough to be up and about (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) are within a healthy range.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a personalized approach to combining chemotherapy and immunotherapy for people with advanced non-small-cell lung cancer that doesn't have certain gene changes. The goal is to find the most effective treatment plan based on your immune system's response.
This trial is testing a personalized treatment for non-small cell lung cancer that uses a patient's own immune cells to fight the tumor. It may help patients with early or advanced stages of the disease.
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
This study looks at how tumors respond to chemotherapy plus immunotherapy before surgery for non-small cell lung cancer. It uses genetic tests on the tumor and blood to personalize treatment and possibly improve outcomes.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.